CelLBxHealth (AGL) Q4 2025 TU earnings summary

Executive summary

• Preliminary unaudited Q4 and FY2025 revenues expected at approximately £1.4 million, with biopharma and product revenues at £0.3 million for the year.

• Some sales contracts worth £0.2 million were deferred to Q1 2026 due to ongoing restructuring.

• Cash balance at year-end 2025 was £7.3 million, supporting ongoing strategic initiatives.

Financial highlights

• FY2025 revenues fell short of the £1.6 million target due to contract deferrals.

• Biopharma and product revenues contributed £0.3 million to the full year.

• Cash position remains strong at £7.3 million as of December 31, 2025.

Outlook and guidance

• Focused on delivering commercial milestones from a qualified 2026 pipeline valued at £12.6 million (risk-weighted at £4.5 million).

• Cost-saving and restructuring measures are expected to drive improved performance in 2026.